929 results on '"Hermans, Cedric"'
Search Results
2. Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany
3. Targeted treatments for vascular malformations: current state of the art
4. Proactive systematic hemophilia carrier screening: a step toward gender equity in hemophilia care
5. The association between unemployment and treatment among adults with hemophilia
6. Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind
7. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
8. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
9. The underevaluated impacts of the therapeutic revolution of hemophilia on women and girls
10. Direct oral anticoagulants and venous malformations: literature review and retrospective study of 29 patients
11. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies
12. The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients
13. Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis
14. Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
15. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study
16. Nonreplacement therapy for hemophilia in low-income countries: experience from a prospective study in Ivory Coast
17. Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective
18. Haemophilia gene therapy: experiences and lessons from treated patients
19. A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results.
20. Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone.
21. The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study
22. Emicizumab as first line therapy in acquired hemophilia A
23. Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A
24. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
25. Women and girls with inherited bleeding disorders: Focus on haemophilia carriers and heavy menstrual bleeding
26. Optimising prophylaxis in haemophilia A: The ups and downs of treatment
27. Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
28. Patient selection for hemophilia gene therapy: Real‐life data from a single center
29. Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection
30. Average Nucleotide Identity and Digital DNA-DNA Hybridization Analysis Following PromethION Nanopore-Based Whole Genome Sequencing Allows for Accurate Prokaryotic Typing.
31. Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries
32. Reliability and construct validity of the ACTIVLIM‐Hemo and Haemophilia Activities List (HAL) questionnaires in individuals with haemophilia
33. The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study
34. The impact of emicizumab on the clinical validation of new therapies for haemophilia A.
35. Impact of uORFs in mediating regulation of translation in stress conditions
36. Experience of a 40-day (6 week) LMWH treatment for isolated distal deep vein thrombosis
37. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
38. Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List
39. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
40. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
41. The value‐based healthcare approach to haemophilia: Development of outcome measures for the evaluation of care of people with haemophilia.
42. The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients
43. Joint status, pain and quality of life in elderly people with haemophilia: A case‐control study
44. New insights into the diagnosis and management of patients with type 2M von Willebrand disease
45. Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic cell transplantation.
46. Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List
47. Haemophilia B: Where are we now and what does the future hold?
48. MariClus: Your One-Stop Platform for Information on Marine Natural Products, Their Gene Clusters and Producing Organisms
49. The 2023 Belgian clinical guidance on anticoagulation management in hospitalized and ambulatory COVID-19 patients
50. Emicizumab for acquired haemophilia A: A case series
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.